Roche Diagnostics is the in vitro diagnostics division of Swiss multinational Roche Holding AG, and represents one of the largest diagnostic companies globally by revenue. Within the neurology franchise, Roche has made substantial investments in Alzheimer's disease and Parkinson's disease biomarker testing through its Elecsys automated immunoassay platform. The company's Elecsys portfolio for neurodegeneration includes assays for amyloid pathology, tau pathology, neurofilament light chain, and neuroinflammation markers, with broad regulatory clearance across major markets. [@roche2024]
Roche's diagnostic strategy in neurodegeneration centers on the concept of enabling earlier and more accurate diagnosis through scalable, automated testing that can be deployed in routine clinical laboratory settings. Unlike research-only platforms (Olink, SomaLogic), Roche's Elecsys is designed as a clinical diagnostic system that integrates into hospital and reference lab workflows, potentially bringing biomarker testing from specialized research centers to broad clinical practice.
The Elecsys platform is Roche's flagship automated immunoassay system, used globally in hospital laboratories, reference labs, and clinical trial settings. The system offers:
High throughput: Random-access testing with up to 170 tests/hour
Automation: Full walkaway capability from sample preparation to result
Broad menu: 200+ assays across clinical chemistry, immunology, oncology, and infectious disease
Global reach: Installed base in 90+ countries with regulatory approvals in major markets (FDA, CE, PMDA)
Quality standards: ISO 13485 certified manufacturing with rigorous QC protocols
[@roche2024]
Neurology Biomarker Menu
Roche's Elecsys neurology menu has expanded rapidly, driven by the AD biomarker revolution:
Tau Pathology:
Elecsys p-tau217 — Phosphorylated tau at threonine 217. One of the most discriminating biomarkers for AD pathology. Roche's p-tau217 assay received FDA breakthrough device designation and is in late-stage clinical validation. Demonstrated >90% accuracy for amyloid PET positivity in large multi-site studies. [@eleu2024]
Elecsys p-tau181 — Phosphorylated tau at threonine 181. CE-marked for clinical use in Europe. Strong performance for distinguishing AD from other neurodegenerative diseases. Used in the EMIF-AD and BioFINDER cohorts for patient stratification. [@schindler2022]
Elecsys total Tau (t-tau) — Neurodegeneration intensity marker, less specific than p-tau variants. Useful in differential diagnosis and as a general neurodegeneration marker within the AT(N) framework.
Amyloid Pathology:
Elecsys Amyloid CSF (Aβ42) — CSF amyloid-beta 42 for amyloid plaque detection. Used with Elecsys Aβ40 for Aβ42/Aβ40 ratio calculation to reduce confounders.
Elecsys Amyloid Plasma Panel — Plasma-based amyloid screening combining Aβ40, Aβ42, and p-tau181 into a ratio for primary care AD risk assessment. Early-stage deployment in primary care settings to triage patients for specialist referral. [@vanbrunt2023]
Neurodegeneration / Neuroaxonal Injury:
Elecsys NfL — Neurofilament light chain for general neuroaxonal injury. Applicable across AD, PD, ALS, FTD, MS, and vascular dementia. Strong prognostic utility for disease progression and treatment response monitoring. [@blennow2024]
Elecsys GFAP — Glial fibrillary acidic protein for astrocyte reactivity. Elevated in AD and other neurodegenerative conditions with neuroinflammatory components.
Synucleinopathies:
Elecsys α-Synuclein — Development-stage assay for total and oligomeric α-synuclein in CSF. Early validation studies show promise for distinguishing PD from atypical parkinsonism. [@maj2019]
Elecsys α-Synuclein seed amplification compatibility — Research collaboration with seed amplification assay developers to combine Elecsys detection with SAA sensitivity.
Key Clinical Evidence
Alzheimer's Disease
Roche GRADUATE program: The gantenerumab GRADUATE trials (NCT03444870, NCT03444857) used Elecsys biomarkers for patient selection and endpoint assessment. Gantenerumab targets aggregated Aβ and showed amyloid clearance in GRADUATE I/II, though primary endpoints were not met. [@roche2024]
p-tau217 validation: Leuzy et al. (2024) demonstrated Roche's Elecsys p-tau217 assay achieved AUC of 0.95-0.98 for detecting amyloid pathology across three independent cohorts (n=1,500+), comparable to the best-performing Lumipulse and Simoa assays. [@eleu2024]
Primary care screening: The Amyloid Plasma Panel (Aβ42/Aβ40 + p-tau181 combination) demonstrated 85% sensitivity and 75% specificity for amyloid PET positivity in primary care populations, enabling pre-screening before specialist referral. [@vanbrunt2023]
Parkinson's Disease and Related Disorders
Cinumercept in MSA: Roche partnered on the AMBAR study of cinumercept in multiple system atrophy (MSA), using Elecsys NfL and other biomarkers for patient stratification and outcome monitoring. Poewe et al. (2025) reported positive signals in the AMBAR study. [@poewe2025]
Neurofilament monitoring: Elecsys NfL elevations in PD correlate with disease severity and predict faster progression, validated in PPMI and independent cohorts.
ALS and FTD
Roche's Elecsys NfL assay is CE-marked for ALS and FTD monitoring. Longitudinal NfL trajectories predict survival in ALS and track with disease progression rate. [@blennow2024]
Strategic Collaborations
AC Immune: Collaboration on anti-Aβ and anti-tau antibody companion diagnostics (gantenerumab, semorinemab)
Alzheimer's Disease Neuroimaging Initiative (ADNI): Roche provides Elecsys biomarker data for ADNI-3 and ADNI-4 longitudinal cohorts
Centers for Medicare & Medicaid Services (CMS): Negotiated reimbursement for amyloid PET and CSF biomarker testing, enabling broader patient access
International Society for Biological and Ageing (ISBA): Cross-validation studies with competing platforms
Pipeline
Roche Diagnostics' neurology pipeline includes:
Next-generation p-tau217: Improved precision assay for clinical diagnostic use (FDA submission planned 2025-2026)
BloodNfL: Plasma neurofilament for ALS and PD monitoring (CE marked)
Combination AD panel: Integrated Aβ42/Aβ40 + p-tau217 + NfL on a single Elecsys cartridge
α-Synuclein seed amplification integration: Combining Elecsys detection technology with SAA methodology
TDP-43 assay: Development-stage assay for ALS and FTD with TDP-43 pathology
AI-assisted result interpretation: Machine learning tools for combining multiple biomarkers into probability scores